Cingulate Inc. (CING) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cingulate Inc. (CING) Healthcare & Pipeline Overview

Cingulate Inc. is a clinical-stage biopharmaceutical company focusing on ADHD treatments, with lead candidates CTx-1301 (dexmethylphenidate) in Phase 3 trials and CTx-1302 (dextroamphetamine) under development. The company aims to provide improved dosing and symptom control for patients with attention-deficit/hyperactivity disorder.

What Is the Investment Thesis for CING?

Cingulate Inc. presents a focused investment opportunity within the ADHD treatment market. The company's lead candidate, CTx-1301, is in Phase 3 clinical trials, representing a near-term catalyst for potential value creation. Positive trial results and subsequent regulatory approval could drive significant revenue growth. The company's second candidate, CTx-1302, offers further pipeline expansion and potential for market diversification. However, the company's small market capitalization of $27.1M and limited resources pose risks. Dependence on successful clinical trial outcomes and regulatory approvals are critical factors. Investor sentiment and market conditions could significantly impact the stock's performance.

Based on FMP financials and quantitative analysis

CING Key Highlights

• CTx-1301, a dexmethylphenidate formulation, is currently in Phase 3 clinical trials for ADHD treatment.
• CTx-1302, a dextroamphetamine formulation, is under development for ADHD, potentially offering a differentiated treatment option.
• The company is also developing CTx-2103 for anxiety disorders, expanding its therapeutic focus.
• Cingulate Inc. operates with a lean team of 13 employees, reflecting a focus on operational efficiency.
• The company's market capitalization is $0.03 billion, indicating its small-cap status.

Who Are CING's Competitors?

CING is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CING's Key Strengths?

• Focus on developing innovative treatments for ADHD.
• Lead product candidate (CTx-1301) in Phase 3 clinical trials.
• Potential for improved dosing and symptom control compared to existing treatments.
• Experienced management team with expertise in drug development.

What Are CING's Weaknesses?

• Limited financial resources and small market capitalization.
• Dependence on successful clinical trial outcomes and regulatory approvals.
• Competition from established pharmaceutical companies with larger market share.
• Limited commercialization experience.

What Could Drive CING Stock Higher?

• Data readout from CTx-1301 Phase 3 clinical trials, expected within the next 12-18 months.
• Potential FDA submission for CTx-1301 following successful Phase 3 results.
• Continued development and advancement of CTx-1302 through preclinical and clinical studies.
• Potential strategic partnerships or collaborations to accelerate drug development.

What Are the Key Risks for CING?

• Financial-distress signal — its Altman Z-Score of -6.99 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in CTx-1301 Phase 3 clinical trials.
• Regulatory setbacks or delays in FDA approval process.
• Competition from established pharmaceutical companies and generic ADHD medications.
• Dependence on securing additional funding to support ongoing clinical trials and operations.

What Are the Growth Opportunities for CING?

• Successful Completion of CTx-1301 Phase 3 Trials: The successful completion of Phase 3 clinical trials for CTx-1301 represents a significant growth opportunity for Cingulate. The timeline for completion and data release is anticipated within the next 12-18 months, making it a near-term catalyst.
• Advancement of CTx-1302 Development: The continued development of CTx-1302, a dextroamphetamine formulation, offers another growth avenue. If successful, CTx-1302 could provide a differentiated treatment option for ADHD patients, expanding Cingulate's product portfolio and market reach. The development timeline is estimated at 2-3 years, with potential for clinical trials and regulatory submissions.
• Expansion into Anxiety Disorder Treatment with CTx-2103: Cingulate's development of CTx-2103 for anxiety disorders represents a strategic diversification opportunity. The anxiety disorder market is substantial, and a successful treatment could significantly expand Cingulate's revenue streams. Clinical trials and regulatory approvals are required, with a timeline of 3-5 years for potential commercialization.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could accelerate Cingulate's drug development programs and provide access to additional funding and expertise. Such collaborations could enhance the company's credibility and increase the likelihood of successful product launches. The timeline for securing partnerships is ongoing and dependent on market conditions and company performance.
• Geographic Expansion: While currently focused on the US market, Cingulate could explore opportunities for geographic expansion into international markets, such as Europe and Asia. This would require regulatory approvals in each region but could significantly increase the company's potential customer base and revenue. The timeline for international expansion is estimated at 5+ years, contingent on successful US commercialization.

What Opportunities Does CING Have?

• Successful commercialization of CTx-1301 and CTx-1302.
• Expansion into new therapeutic areas, such as anxiety disorders.
• Strategic partnerships with larger pharmaceutical companies.
• Increasing prevalence of ADHD and demand for improved treatments.

What Threats Does CING Face?

• Failure to achieve positive clinical trial results.
• Regulatory setbacks and delays in drug approval.
• Competition from generic ADHD medications.
• Changes in healthcare regulations and reimbursement policies.

What Are CING's Competitive Advantages?

• Proprietary drug formulations with potential for improved efficacy and safety.
• Patent protection for their drug candidates, providing market exclusivity.
• Clinical trial data demonstrating the benefits of their treatments.
• First-mover advantage in developing specific ADHD treatment options.

What Does CING Do?

Founded in 2012 and headquartered in Kansas City, Kansas, Cingulate Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for attention-deficit/hyperactivity disorder (ADHD). The company's mission is to address the unmet needs of patients with ADHD by developing product candidates that offer improved dosing regimens and symptom control. Cingulate's lead product candidates include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to provide a rapid onset and extended duration of effect. CTx-1301 is currently in Phase 3 clinical trials. Additionally, Cingulate is developing CTx-2103 for the treatment of anxiety disorders, expanding its focus beyond ADHD. The company's pipeline reflects its commitment to addressing a range of mental health conditions with significant unmet medical needs. Cingulate operates with a lean team of 13 employees, emphasizing efficiency and strategic partnerships to advance its clinical programs.

What Products and Services Does CING Offer?

• Develop product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD).
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Focus on developing improved dosing regimens and symptom control for ADHD patients.
• Advance CTx-1301 (dexmethylphenidate) through Phase 3 clinical trials.
• Develop CTx-1302 (dextroamphetamine) as another potential ADHD treatment option.
• Explore treatments for anxiety disorders with CTx-2103.

How Does CING Make Money?

• Develop and patent novel drug formulations for ADHD and anxiety disorders.
• Conduct clinical trials to demonstrate the safety and efficacy of their drug candidates.
• Seek regulatory approval from the FDA for commercialization.
• Potentially partner with larger pharmaceutical companies for manufacturing and distribution.

What Industry Does CING Operate In?

The biotechnology industry is characterized by high risk and high reward, with companies like Cingulate Inc. focused on developing novel therapies for specific medical conditions. The ADHD treatment market is a significant segment within the broader pharmaceutical landscape, driven by increasing diagnosis rates and demand for improved treatment options. Competition includes established pharmaceutical companies and other emerging biotech firms developing innovative ADHD therapies. Cingulate's success depends on its ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy and safety of its product candidates.

Who Are CING's Key Customers?

• Patients diagnosed with attention-deficit/hyperactivity disorder (ADHD).
• Healthcare providers who prescribe ADHD medications.
• Pharmacies that dispense ADHD medications.
• Potentially, patients with anxiety disorders if CTx-2103 is approved.

FY2026 estForward Outlook

Wall Street analysts project Cingulate Inc. revenue of about $2.9M for fiscal 2026, with EPS near $-2.42. The estimate reflects 3 contributing analysts.

F-Score 3/9Financial Health

Cingulate Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.99 places it in the distress zone, a signal of elevated financial risk.

Cingulate Inc. (CING) Valuation Context

Relative to its peer group, CING's quantitative score of 28/100 is below the peer average of 75/100.

CING Financials

CING Latest News

CING Analyst Consensus

CING MoonshotScore

Cingulate Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources